BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 30420667)

  • 1. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.
    Bacher U; Shumilov E; Flach J; Porret N; Joncourt R; Wiedemann G; Fiedler M; Novak U; Amstutz U; Pabst T
    Blood Cancer J; 2018 Nov; 8(11):113. PubMed ID: 30420667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.
    Patel U; Luthra R; Medeiros LJ; Patel KP
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S62-S74. PubMed ID: 28760304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
    Kohlmann A; Bacher U; Schnittger S; Haferlach T
    Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current concepts and future directions for hemato-oncologic diagnostics.
    Flach J; Shumilov E; Joncourt R; Porret N; Novak U; Pabst T; Bacher U
    Crit Rev Oncol Hematol; 2020 Jul; 151():102977. PubMed ID: 32446181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
    Hughes CFM; Gallipoli P; Agarwal R
    Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular findings in myeloid neoplasms.
    Tran TB; Siddon AJ
    Int J Lab Hematol; 2023 Aug; 45(4):442-448. PubMed ID: 37345257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.
    Bhai P; Hsia CC; Schenkel LC; Hedley BD; Levy MA; Kerkhof J; Santos S; Stuart A; Lin H; Broadbent R; Nan S; Yang P; Xenocostas A; Chin-Yee I; Sadikovic B
    Mol Diagn Ther; 2022 May; 26(3):333-343. PubMed ID: 35381971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies.
    Jiang L; Pallavajjala A; Huang J; Haley L; Morsberger L; Stinnett V; Hardy M; Park R; Ament C; Finch A; Shane A; Parish R; Nozari A; Long P; Adams E; Smith K; Parimi V; Dougaparsad S; Long L; Gocke CD; Zou YS
    J Mol Diagn; 2021 Apr; 23(4):467-483. PubMed ID: 33577993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
    Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
    Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Molecular and Genetic Diagnostics of Myeloid Malignancies with Emphasis on Diagnostics in Bosnia and Herzegovina.
    Kurtovic-Kozaric A; Islamagic E; Asic A; Mehinovic-Cavcic L; Besic L; Sahinbegovic H; Komic H; Kurtovic S; Burazerovic L
    Acta Med Acad; 2021 Apr; 50(1):175-196. PubMed ID: 34075772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germ line predisposition to myeloid malignancies appearing in adulthood.
    Crysandt M; Brings K; Beier F; Thiede C; Brümmendorf TH; Jost E
    Expert Rev Hematol; 2018 Aug; 11(8):625-636. PubMed ID: 29958021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and trends in the diagnostics of AML and MDS.
    Shumilov E; Flach J; Kohlmann A; Banz Y; Bonadies N; Fiedler M; Pabst T; Bacher U
    Blood Rev; 2018 Nov; 32(6):508-519. PubMed ID: 29728319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias).
    Hasserjian RP; Kelley TW; Weinberg OK; Morgan EA; Fend F
    Am J Clin Pathol; 2019 Aug; 152(3):302-321. PubMed ID: 31263893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice.
    Northrup V; Maybank A; Carson N; Rahmeh T
    Am J Clin Pathol; 2020 Apr; 153(5):639-645. PubMed ID: 31875888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.
    Zuo Z; Li S; Xu J; You MJ; Khoury JD; Yin CC
    Curr Hematol Malig Rep; 2019 Oct; 14(5):376-385. PubMed ID: 31388824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
    Vantyghem S; Peterlin P; Thépot S; Ménard A; Dubruille V; Debord C; Guillaume T; Garnier A; Le Bourgeois A; Wuilleme S; Godon C; Theisen O; Eveillard M; Delaunay J; Maisonneuve H; Morineau N; Villemagne B; Vigouroux S; Subiger F; Lestang E; Loirat M; Parcelier A; Godmer P; Mercier M; Trebouet A; Luque Paz D; Le Calloch R; Le Clech L; Bossard C; Moreau A; Ugo V; Hunault M; Moreau P; Le Gouill S; Chevallier P; Béné MC; Le Bris Y
    Haematologica; 2021 Mar; 106(3):701-707. PubMed ID: 32241844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.